Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Sucunamostat in Healthy Subjects
NCT02448719Phase 1Completed
- Sponsor
- Takeda
- Start
- May 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Sucunamostat in type 2 diabetes mellitus (T2DM) and obesity (12 cohorts), sponsored by Takeda. Primary endpoints: Treatment Emergent Adverse Events at Day 8, TEAE Related to Vital Signs at Day 5 and 3 more. Started May 2015; status: completed.
02
Drugs
Sucunamostat
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT02448719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02448719.